Sarepta Commits To Rapid, Thorough Pivotal Study For DMD Gene Therapy Based On Functional Improvements

The company presented encouraging data on functional assessments of four boys treated with a micro-dystrophin gene therapy at the World Muscle Society, furthering momentum around the program.

Development Attainment Motivation Career Growth Concept. Mans Hand Reaching For Red Ladder Leading To A Blue Sky

Sarepta Therapeutics Inc. already presented positive data in June for its micro-dystrophin gene therapy in three boys with Duchenne Muscular Dystrophy, showing positive results on gene expression and biomarkers, but the company released the first data from functional assessments Oct. 4 at the World Muscle Society Congress.

The data were encouraging across endpoints like the North Star Ambulatory Assessment (NSAA) scale, time to rise, four stairs up...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Rare Diseases

Sanofi Revels In More Positive Rilzabrutinib Data

 
• By 

The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.

Biogen Lays Out Cadence For Felzartamab Data In Kidney Diseases

 

The first Phase III data for the CD38-targeting antibody is expected in 2027 in antibody-mediated rejection in kidney transplant patients, followed by other indications.

Vigil’s Iluzanebart Disappoints In Rare Neurodegenerative Disease

 

The Phase II TREM2 agonist is not part of Sanofi’s planned acquisition.

Sanofi Plays It Safer With Blueprint Buy After Bumpy 2025

 
• By 

But the French major is still keen on early-stage M&A.

More from Scrip